middle.news
Cleo Diagnostics Starts Manufacturing Program with Bio-Techne Ahead of FDA Submission
9:02am on Tuesday 28th of April, 2026 AEST
•
Healthcare
Read Story
Cleo Diagnostics Starts Manufacturing Program with Bio-Techne Ahead of FDA Submission
9:02am on Tuesday 28th of April, 2026 AEST
Key Points
Staged manufacturing program underway with Bio-Techne
Transition from clinical trial sample collection to analytical validation
Focus on assay component optimisation to reduce production risks
Collaboration leverages Bio-Techne’s Ella™ platform expertise
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cleo Diagnostics (ASX:COV)
OPEN ARTICLE